B V Patel Pharmaceutical Educational and Research Development (PERD) Centre here has developed a new capsule for the treatment of tuberculosis which they claim could cut short treatment duration from an average six months to three.
"The capsule comprising new formulation of Rifampacin and Isoniazid is designed for targeted drug delivery in stomach and intestine respectively of the patients, and its initial trials have shown very encouraging results," PERD Honorary Director, Prof C J Shishoo told PTI.
"The drug was tested on 12 healthy volunteers here, where we checked how much drug is reaching in their blood," he said. "The clinical trials of this new drug are now scheduled to begin at All India Institute of Medical Sciences (AIIMS) at New Delhi,....................&more
No comments:
Post a Comment